-
PloS One 2017Nitric oxide synthase (NOS) is a biomarker/target in sepsis. NOS activity is driven by amino acids, which cycle to regulate the substrate L-arginine in parallel with...
RATIONALE
Nitric oxide synthase (NOS) is a biomarker/target in sepsis. NOS activity is driven by amino acids, which cycle to regulate the substrate L-arginine in parallel with cycles which regulate the endogenous inhibitors ADMA and L-NMMA. The relationship between amines and the consequence of plasma changes on iNOS activity in early sepsis is not known.
OBJECTIVE
Our objective was to apply a metabolomics approach to determine the influence of sepsis on a full array of amines and what consequence these changes may have on predicted iNOS activity.
METHODS AND MEASUREMENTS
34 amino acids were measured using ultra purification mass spectrometry in the plasma of septic patients (n = 38) taken at the time of diagnosis and 24-72 hours post diagnosis and of healthy volunteers (n = 21). L-arginine and methylarginines were measured using liquid-chromatography mass spectrometry and ELISA. A top down approach was also taken to examine the most changed metabolic pathways by Ingenuity Pathway Analysis. The iNOS supporting capacity of plasma was determined using a mouse macrophage cell-based bioassay.
MAIN RESULTS
Of all the amines measured 22, including L-arginine and ADMA, displayed significant differences in samples from patients with sepsis. The functional consequence of increased ADMA and decreased L-arginine in context of all cumulative metabolic changes in plasma resulted in reduced iNOS supporting activity associated with sepsis.
CONCLUSIONS
In early sepsis profound changes in amine levels were defined by dominant changes in the iNOS canonical pathway resulting in functionally meaningful changes in the ability of plasma to regulate iNOS activity ex vivo.
Topics: Adult; Aged; Amines; Animals; Arginine; Cell Line; Chromatography, Liquid; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Mass Spectrometry; Metabolomics; Mice; Middle Aged; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Sepsis; omega-N-Methylarginine
PubMed: 28813479
DOI: 10.1371/journal.pone.0183025 -
American Journal of Physiology.... Oct 2012Studies of experimental diabetes mellitus (DM) suggest that increased nitric oxide (NO) bioactivity contributes to renal hyperfiltration. However, the role of NO in...
Studies of experimental diabetes mellitus (DM) suggest that increased nitric oxide (NO) bioactivity contributes to renal hyperfiltration. However, the role of NO in mediating hyperfiltration has not been fully elucidated in humans. Our aim was to examine the effect of NO synthase inhibition on renal and peripheral vascular function in normotensive subjects with uncomplicated type 1 DM. Renal function and brachial artery flow-mediated vasodilatation (FMD) were measured before and after an intravenous infusion of the NO synthase inhibitor N(G)-nitro-l-arginine methyl ester (l-NMMA) in 21 healthy control and 37 type 1 DM patients. Measurements in DM participants were made under clamped euglycemic conditions. The effect of l-NMMA on circulating and urinary NO metabolites (NO(x)) and cGMP and on urinary prostanoids was also determined. Baseline characteristics were similar in the two groups. For analysis, the DM patients were divided into those with hyperfiltration (DM-H, n = 18) and normal glomerular filtration rate (GFR) levels (DM-N, n = 19). Baseline urine NO(x) and cGMP were highest in DM-H. l-NMMA led to a decline in GFR in DM-H (152 ± 16 to 140 ± 11 ml·min(-1)·1.73 m(-2)) but not DM-N or healthy control participants. The decline in effective renal plasma flow in response to l-NMMA (806 ± 112 to 539 ± 80 ml·min(-1)·1.73 m(-2)) in DM-H was also exaggerated compared with the other groups (repeated measures ANOVA, P < 0.05), along with declines in urinary NO(x) metabolites and cGMP. Baseline FMD was lowest in DM-H compared with the other groups and did not change in response to l-NMMA. l-NMMA reduced FMD and plasma markers of NO bioactivity in the healthy control and DM-N groups. In patients with uncomplicated type 1 DM, renal hyperfiltration is associated with increased NO bioactivity in the kidney and reduced NO bioactivity in the systemic circulation, suggesting a paradoxical state of high renal and low systemic vascular NO bioactivity.
Topics: Adult; Brachial Artery; Cyclic AMP; Diabetes Mellitus, Type 1; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Infusions, Intravenous; Kidney; Male; Nitric Oxide; Nitric Oxide Synthase; Renal Circulation; Vasodilation; omega-N-Methylarginine
PubMed: 22855276
DOI: 10.1152/ajpregu.00286.2012 -
The Journal of Biological Chemistry May 1998The production of NO. by mitochondria was investigated by electron paramagnetic resonance using the spin-trapping technique, and by the oxidation of oxymyoglobin....
The production of NO. by mitochondria was investigated by electron paramagnetic resonance using the spin-trapping technique, and by the oxidation of oxymyoglobin. Percoll-purified rat liver mitochondria exhibited a negligible contamination with other subcellular fractions (1-4%) and high degree of functionality (respiratory control ratio = 5-6). Toluene-permeabilized mitochondria, mitochondrial homogenates, and a crude preparation of nitric oxide synthase (NOS) incubated with the spin trap N-methyl-D-glucamine-dithiocarbamate-FeII produced a signal ascribed to the NO. spin adduct (g = 2.04; aN = 12.5 G). The intensity of the signal increased with time, protein concentration, and L-Arg, and decreased with the addition of the NOS inhibitor NG-monomethyl-L-arginine. Intact mitochondria, mitochondrial homogenates, and submitochondrial particles produced NO. (followed by the oxidation of oxymyoglobin) at rates of 1.4, 4.9, and 7.1 nmol NO. x (min.mg protein)-1, respectively, with a Km for L-Arg of 5-7 microM. Comparison of the rates of NO. production obtained with homogenates and submitochondrial particles indicated that most of the enzymatic activity was localized in the mitochondrial inner membrane. This study demonstrates that mitochondria are a source of NO., the production of which may effect energy metabolism, O2 consumption, and O2 free radical formation.
Topics: Animals; Diffusion; Electron Spin Resonance Spectroscopy; Enzyme Inhibitors; Intracellular Membranes; Mitochondria, Liver; Myoglobin; Nitric Oxide; Nitric Oxide Synthase; Oxidation-Reduction; Permeability; Rats; Rats, Wistar; Spin Labels; omega-N-Methylarginine
PubMed: 9556586
DOI: 10.1074/jbc.273.18.11038 -
Arteriosclerosis, Thrombosis, and... Jun 2012The asymmetric methylarginines inhibit nitric oxide synthesis in vivo by competing with L-arginine at the active site of nitric oxide synthase. High circulating levels... (Review)
Review
The asymmetric methylarginines inhibit nitric oxide synthesis in vivo by competing with L-arginine at the active site of nitric oxide synthase. High circulating levels of asymmetric dimethylarginine predict adverse outcomes, specifically vascular events but there is now increasing experimental and epidemiological evidence that these molecules, and the enzymes that regulate this pathway, play a mechanistic role in cardiovascular diseases. Recent data have provided insight into the impact of altered levels of these amino acids in both humans and rodents, however these reports also suggest a simplistic approach based on measuring, and modulating circulating asymmetric dimethylarginine alone is inadequate. This review outlines the basic biochemistry and physiology of endogenous methylarginines, examines both the experimental and observational evidence for a role in disease pathogenesis, and examines the potential for therapeutic regulation of these molecules.
Topics: Amidohydrolases; Animals; Arginine; Binding Sites; Binding, Competitive; Biomarkers; Cardiovascular Agents; Cardiovascular Diseases; Catalytic Domain; Enzyme Inhibitors; Humans; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine
PubMed: 22460557
DOI: 10.1161/ATVBAHA.112.247726 -
Journal of the American College of... Feb 1998This study was undertaken to test the hypothesis that lipoprotein(a) [Lp(a)] impairs endothelial function.
OBJECTIVES
This study was undertaken to test the hypothesis that lipoprotein(a) [Lp(a)] impairs endothelial function.
BACKGROUND
Elevated Lp(a) plasma levels have been demonstrated to be associated with an increased risk of coronary heart disease. In atherosclerosis, endothelial dysfunction is known to be an early indicator of vascular changes. However, the effect of Lp(a) on nitric oxide (NO)-dependent vasodilator response has not yet been determined. We therefore examined the influence of Lp(a) on basal and stimulated NO-mediated vasodilator response in the forearm vascular bed.
METHODS
Strain gauge plethysmography was used to measure changes in forearm blood flow produced by intraarterial infusion of increasing doses of acetylcholine (3, 12, 24 and 48 microg/min), sodium nitroprusside (200, 800 and 3,200 ng/min) and N-monomethyl L-arginine (L-NMMA) (1, 2 and 4 micromol/min) in 57 white subjects (mean age +/- SD 37 +/- 14 years). Lp(a) plasma concentrations were determined by rocket immunoelectrophoresis.
RESULTS
Endothelium-dependent vasodilation tested by intraarterial acetylcholine and endothelium-independent vascular relaxation tested by intraarterial sodium nitroprusside were not correlated with Lp(a). Similarly, no significant differences in forearm blood flow changes were observed when patients were classified into tertiles according to their individual Lp(a) concentration. In contrast, changes in forearm blood flow after intraarterial L-NMMA indicating basal production and release of NO differed significantly among tertiles. Patients in the highest Lp(a) tertile (49.2 +/- 20.3 mg/dl) had a much greater vasoconstrictive response to L-NMMA than patients in the lowest Lp(a) tertile (4.8 +/- 2.5 mg/dl): 2 micromol/min of L-NMMA, -23.6 +/- 22.5% vs. -10.4 +/- 9.1% (p < 0.02); 4 micromol/min of L-NMMA, -27.8 +/- 10.3% vs. -17.6 +/- 9.9% (p < 0.03). Lp(a) plasma level consistently correlated negatively with the forearm blood flow responses to 4 micromol/min of intraarterial L-NMMA (r = -0.38, p < 0.01). Multiple stepwise regression analysis of variables, including total and high and low density lipoprotein cholesterol, further confirmed that plasma Lp(a) remained a significant independent determinant of forearm blood flow changes in response to L-NMMA (p < 0.02).
CONCLUSIONS
The endothelium-dependent vasoconstrictive response to L-NMMA was enhanced in subjects with relatively high Lp(a) plasma levels, suggesting an increased basal production and release of NO. This response seemed to reflect a compensatory mechanism of the endothelium to yet unknown Lp(a)-induced atherosclerotic effects.
Topics: Acetylcholine; Adult; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Enzyme Inhibitors; Female; Forearm; Humans; Immunoelectrophoresis; Infusions, Intra-Arterial; Lipoprotein(a); Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Nitroprusside; Plethysmography; Regional Blood Flow; Regression Analysis; Risk Factors; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; omega-N-Methylarginine
PubMed: 9462580
DOI: 10.1016/s0735-1097(97)00497-x -
The Journal of Toxicological Sciences 2020Bisphenol A (BPA) interferes the function and development of the central nervous system (CNS), resulting in behavioral abnormalities and memory loss. S-nitrosylation of...
Bisphenol A and rotenone induce S-nitrosylation of protein disulfide isomerase (PDI) and inhibit neurite outgrowth of primary cultured cells of the rat hippocampus and PC12 cells.
Bisphenol A (BPA) interferes the function and development of the central nervous system (CNS), resulting in behavioral abnormalities and memory loss. S-nitrosylation of protein disulfide isomerase (PDI) is increased in brains with sporadic Alzheimer's disease and Parkinson's disease. The aim of the present study was to clarify the role of nitric oxide (NO) in BPA-induced neurotoxicity. Since rotenone induces NO-mediated neurodegeneration through S-nitrosylation of PDI, it was used as a positive control. First, rats were treated with BPA and rotenone, and S-nitrosylation of PDI was detected in rat brain microsomes. BPA and rotenone decreased RNase oxidation activity of PDI concomitant with S-nitrosylation of PDI. Next, to clarify S-nitrosylation of PDI by BPA and rotenone in rat brains, we treated the rat pheochromocytoma cell line PC12 and primary cultured neuron cells from the rat hippocampus with BPA (5 and 10 μM) and rotenone (100 or 200 nM). BPA induced S-nitrosylation of PDI, while NG-monomethyl-L-arginine (L-NMMA), a NOS inhibitor, exerted the opposite effects. Finally, to evaluate the toxicity of BPA in the CNS, we investigated its effects on neurite outgrowth of PC12 and primary cultured neuron cells. BPA inhibited neurite outgrowth of these cells, while L-NMMA reversed this inhibition. The involvement of PDI activity in neurite outgrowth was also examined, and bacitracin, a PDI inhibitor, is shown to decrease neurite outgrowth. Furthermore, the overexpression of PDI, but not a catalytically inactive PDI mutant, enhanced neurite outgrowth. These results suggested that S-nitrosylation of PDI induced by excessive NO caused BPA-induced neurotoxicity.
Topics: Animals; Benzhydryl Compounds; Brain; Depression, Chemical; Hippocampus; Male; Neuronal Outgrowth; Neurotoxins; Nitric Oxide; Oxidation-Reduction; PC12 Cells; Phenols; Protein Disulfide-Isomerases; Rats; Rats, Sprague-Dawley; Ribonucleases; Rotenone; omega-N-Methylarginine
PubMed: 33268678
DOI: 10.2131/jts.45.783 -
Osteoarthritis and Cartilage Oct 2012Chondrocyte apoptosis represents an important component in the osteoarthritis (OA) pathogenesis. This study sought to investigate the potential of polychlorinated...
OBJECTIVE
Chondrocyte apoptosis represents an important component in the osteoarthritis (OA) pathogenesis. This study sought to investigate the potential of polychlorinated biphenyl (PCB)126, the most potent and ubiquitous environmental pollutant of PCB congeners, on chondrocyte apoptosis and its mechanism of action.
METHODS
Rabbit articular chondrocytes cultured from tibial and femoral in cartilage were exposed to PCB126. Productions of reactive oxygen species (ROS) and nitric oxide (NO) and nuclear factor-kB (NF-kB) binding activity were measured. After 24 h exposure to PCB126, the apoptotic cell death was detected by caspase-3 activity, enzyme-linked immunosorbent assay (ELISA) using antibodies against DNA and histone, and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end-labeling (TUNEL) staining.
RESULTS
PCB126 generated ROS, which was blocked by the antioxidants (N-acetylcystein and trolox), or the aryl hydrocarbon receptor (AhR) inhibitor, α-naphthoflavone (α-NF). PCB126 exposure also increased NO production and NF-kB binding activity in the chondrocytes, which were blocked by the iNOS inhibitor, N-monomethyl-l-arginine (l-NMMA). All apoptosis detection techniques used in this study revealed an increase of apoptotic effects by PCB126 exposure, which was blocked by inhibitors of ROS or iNOS. This is the first report to demonstrate the potential of a PCB congener to induce chondrocytes apoptosis, which could be an initial process in cartilage degradation.
CONCLUSIONS
PCB may be an initiator of chondrocyte apoptosis, which is closely linked to degradation of cartilage in OA pathogenesis. This study may contribute to identifying the possible causes of arthritis in our environment.
Topics: Acetylcysteine; Animals; Antioxidants; Apoptosis; Benzoflavones; Cells, Cultured; Chondrocytes; Chromans; Drug Antagonism; Enzyme Inhibitors; Estrogen Antagonists; NF-kappa B; Nitric Oxide; Polychlorinated Biphenyls; Rabbits; Reactive Oxygen Species; omega-N-Methylarginine
PubMed: 22750746
DOI: 10.1016/j.joca.2012.06.004 -
BMC Neurology Dec 2010Migraine has been associated with cardiovascular disorders. Endothelial dysfunction may be a mechanism underlying this association. The present study tested the...
BACKGROUND
Migraine has been associated with cardiovascular disorders. Endothelial dysfunction may be a mechanism underlying this association. The present study tested the hypothesis that endothelium-dependent vasodilation, basal endothelial nitric oxide release and endothelial fibrinolytic capacity are impaired in migraine patients.
METHODS
Graded doses of sodium nitroprusside (SNP, 0.2 to 0.8 μg x min(-1) x dL(-1) forearm), substance P (0.2 to 0.8 pmol x min(-1) x dL(-1) forearm) and N(G)-monomethyl-L-arginine (L-NMMA, 0.1 to 0.4 μmol x min(-1) x dL(-1) forearm) were infused into the brachial artery of 16 migraine patients with or without aura during a headache-free interval and 16 age- and sex-matched subjects without a history of migraine. Forearm blood flow (FBF) was measured by strain-gauge venous occlusion plethysmography. Local forearm release of tissue plasminogen activator (t-PA) in response to substance P infusion was assessed using the arteriovenous plasma concentration gradient. Responses to infused drugs were compared between patients and matched controls by analysis of variance.
RESULTS
In both migraine patients and control subjects, SNP and substance P caused a dose-dependent increase, and L-NMMA a dose-dependent decrease in FBF (P < 0.001 for all responses). In both groups, substance P caused an increase in t-PA release (P < 0.001). FBF responses and t-PA release were comparable between migraine patients and control subjects.
CONCLUSIONS
The absence of differences in endothelium-dependent vasodilation, basal endothelial nitric oxide production and stimulated t-PA release between migraine patients and healthy control subjects argues against the presence of endothelial dysfunction in forearm resistance vessels of migraine patients.
Topics: Adult; Analysis of Variance; Cross-Sectional Studies; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Forearm; Humans; Male; Migraine Disorders; Nitroprusside; Regional Blood Flow; Substance P; Tissue Plasminogen Activator; Vasodilation; omega-N-Methylarginine
PubMed: 21122149
DOI: 10.1186/1471-2377-10-119 -
Nitric Oxide : Biology and Chemistry Nov 2020Nitric oxide synthase (NOS) inhibition with N(G)-monomethyl-l-arginine (L-NMMA) is often used to assess the role of NO in human cardiovascular function. However, the...
Nitric oxide synthase (NOS) inhibition with N(G)-monomethyl-l-arginine (L-NMMA) is often used to assess the role of NO in human cardiovascular function. However, the window of effect for L-NMMA on human vascular function is unknown, which is critical for designing and interpreting human-based studies. This study utilized the passive leg movement (PLM) assessment of vascular function, which is predominantly NO-mediated, in 7 young male subjects under control conditions, immediately following intra-arterial L-NMMA infusion (0.24 mg⋅dl⋅min), and at 45-60 and 90-105 min post L-NMMA infusion. The leg blood flow (LBF) and leg vascular conductance (LVC) responses to PLM, measured with Doppler ultrasound and expressed as the change from baseline to peak (ΔLBF and ΔLVC) and area under the curve (LBF and LVC), were assessed. PLM-induced robust control ΔLBF (1135 ± 324 ml⋅min) and ΔLVC (10.7 ± 3.6 ml⋅min⋅mmHg) responses that were significantly attenuated (704 ± 196 ml⋅min and 6.7 ± 2 ml⋅min⋅mmHg) immediately following L-NMMA infusion. Likewise, control condition PLM ΔLBF (455 ± 202 ml) and ΔLVC (4.0 ± 1.4 ml⋅mmHg) were significantly attenuated (141 ± 130 ml and 1.3 ± 1.2 ml⋅mmHg) immediately following L-NMMA infusion. However, by 45-60 min post L-NMMA infusion all PLM variables were not significantly different from control, and this was still the case at 90-105 min post L-NMMA infusion. These findings reveal that the potent reduction in NO bioavailability afforded by NOS inhibition with L-NMMA has a window of effect of less than 45-60 min in the human vasculature. These data are particularly important for the commonly employed approach of pharmacologically inhibiting NOS with L-NMMA in the human vasculature.
Topics: Adult; Enzyme Inhibitors; Femoral Artery; Hemodynamics; Humans; Leg; Male; Nitric Oxide; Nitric Oxide Synthase; Regional Blood Flow; Time Factors; Young Adult; omega-N-Methylarginine
PubMed: 32979497
DOI: 10.1016/j.niox.2020.09.001 -
PloS One 2015Glucagon levels are often moderately elevated in diabetes. It is known that glucagon leads to a decrease in hepatic glutathione (GSH) synthesis that in turn is...
Glucagon levels are often moderately elevated in diabetes. It is known that glucagon leads to a decrease in hepatic glutathione (GSH) synthesis that in turn is associated with decreased postprandial insulin sensitivity. Given that cAMP pathway controls GSH levels we tested whether insulin sensitivity decreases after intraportal (ipv) administration of a cAMP analog (DBcAMP), and investigated whether glucagon promotes insulin resistance through decreasing hepatic GSH levels.Insulin sensitivity was determined in fed male Sprague-Dawley rats using a modified euglycemic hyperinsulinemic clamp in the postprandial state upon ipv administration of DBcAMP as well as glucagon infusion. Glucagon effects on insulin sensitivity was assessed in the presence or absence of postprandial insulin sensitivity inhibition by administration of L-NMMA. Hepatic GSH and NO content and plasma levels of NO were measured after acute ipv glucagon infusion. Insulin sensitivity was assessed in the fed state and after ipv glucagon infusion in the presence of GSH-E. We founf that DBcAMP and glucagon produce a decrease of insulin sensitivity, in a dose-dependent manner. Glucagon-induced decrease of postprandial insulin sensitivity correlated with decreased hepatic GSH content and was restored by administration of GSH-E. Furthermore, inhibition of postprandial decrease of insulin sensitivity L-NMMA was not overcome by glucagon, but glucagon did not affect hepatic and plasma levels of NO. These results show that glucagon decreases postprandial insulin sensitivity through reducing hepatic GSH levels, an effect that is mimicked by increasing cAMP hepatic levels and requires physiological NO levels. These observations support the hypothesis that glucagon acts via adenylate cyclase to decrease hepatic GSH levels and induce insulin resistance. We suggest that the glucagon-cAMP-GSH axis is a potential therapeutic target to address insulin resistance in pathological conditions.
Topics: Adenylyl Cyclases; Animals; Blood Glucose; Bucladesine; Cyclic AMP; Dose-Response Relationship, Drug; Glucagon; Glucose Clamp Technique; Glutathione; Injections, Intravenous; Insulin; Insulin Resistance; Liver; Male; Nitric Oxide; Portal Vein; Postprandial Period; Rats; Rats, Sprague-Dawley; omega-N-Methylarginine
PubMed: 25961284
DOI: 10.1371/journal.pone.0127221